NOVEL AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUP AND ANTIFUNGAL PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a derivative compound in which a biphenyl group is introduced into an aminoalkanoic acid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent antifungal and fungicidal effects. Furthermore, the compound of the present invention exhibits a synergistic effect when used in combination with a conventional antifungal agent. Furthermore, the compound of the present invention provides broad-spectrum antifungal activity against a wide range of fungal pathogens. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

Use of the Genes in the Hog, Ras and cAMP Pathway for Treatment Of Fungal Infection

Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited. Therefore, an antifungal pharmaceutical composition including an inhibitor against the gene or protein encoded by the same can be used as an excellent combined antifungal agent which can reduce a conventional amount of an antifungal agent used and increase an efficiency. 1. A method of screening an antifungal agent for improving a fungal killing ability when used with an ergosterol-binding antifungal agent or azole-based antifungal agent , comprising:{'i': 'Cryptococcus neoformans', 'contacting Ssk1 protein of with a candidate material; and'}determining whether the candidate material inhibits or stimulates an activity of the protein.2. The method of claim 1 , wherein the ergosterol-binding antifungal agent is a polyene-based antifungal agent.3. The method of claim 2 , wherein the polyene-based antifungal agent is at least one selected from the group consisting of amphotericin B claim 2 , natamycin claim 2 , rimocidin claim 2 , filipin claim 2 , nystatin claim 2 , and candicin.4. The method of claim 2 , wherein the polyene-based antifungal agent is amphotericin B.5. The method of claim 1 , wherein the azole-based antifungal agent is at least one ...

Fungicidal effect by regulating signal transduction pathways

The present invention concerns methods of treating fungal infections and methods of screening compounds for activity in treating fungal infections. Methods of the invention include using an active compound such as fludioxonil to treat a Cryptococcus neoformans infection. Also included are methods and pharmaceutical compositions useful for treating fungal infections using a Hog1 activator such as fludioxonil and a calcineurin inhibitor in combination.

Use of the genes in the Hog, Ras and cAMP pathway for treatment of fungal infection

Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus neoformans, roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of Cryptococcus neoformans, roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited. Therefore, an antifungal pharmaceutical composition including an inhibitor against the gene or protein encoded by the ...

FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to novel functional derivatives of alanine and proline amino acids. The compounds of the present invention were confirmed to have a very superior antifungal or fungicidal effect. In addition, the compounds of the present invention were confirmed to exhibit a synergistic effect when co-administered with an existing antifungal preparation. Moreover, the compounds of the present invention showed activity on a wide range of fungi. Therefore, the compounds of the present invention can be widely used in a field which requires the treatment with an antifungal or fungicidal preparation against human infectious fungi, animal infectious fungi, and phytopathogenic fungi.

USE OF THE GENES IN THE HOG, Ras AND cAMP PATHWAY FOR TREATMENT OF FUNGAL INFECTION

Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of , roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of , roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited. Therefore, an antifungal pharmaceutical composition including an inhibitor against the gene or protein encoded by the same can be used as an excellent combined antifungal agent which can reduce a conventional amount of an antifungal agent used and increase an efficiency. 1. A method of treating fungal infection , comprising:{'i': 'Cryptococcus neoformans', 'injecting an effective amount of an inhibitor against at least one protein selected from the group consisting of Ssk1, Tco2, Ssk2, Pbs2, Hog1, Ena1 and Nha1 of into a subject.'}2. The method of treating fungal infection of claim 1 , wherein the inhibitor against at least one protein selected from the group consisting of Ssk1 claim 1 , Ena1 and Nha1.3. The method of treating fungal infection of claim 1 , wherein an ergosterol-binding antifungal agent or azole-based antifungal agent is sequentially or simultaneously injected with the inhibitor.4. The method of treating fungal infection of claim 3 , wherein the ergosterol-binding antifungal agent is a polyene-based antifungal agent.5. The method of treating fungal infection of claim 4 , wherein the polyene-based antifungal agent is at least one ...

NOVEL KINASE FOR TREATING AND PREVENTING FUNGAL INFECTIONS, AND USE THEREOF

The present invention relates to a use of kinases for treating and preventing fungal meningoencephalitis by pathogenic fungi of the genus Cryptococcus. Specifically, the present invention relates to a method for screening an antifungal agent characterized by measuring the amount or activity of a pathogenic-regulatory kinase protein of Cryptococcus neoformans, or the expression level of a gene encoding the protein; and an antifungal pharmaceutical composition comprising an inhibitor against a pathogenic-regulatory kinase protein of Cryptococcus neoformans or a gene encoding the same. An antifungal agent for treating meningoencephalitis, etc. can be effectively screened by using the method for screening an antifungal agent according to the present invention, and meningoencephalitis, etc. can be effectively treated by using the antifungal pharmaceutical composition according to the present invention. Thus, the present invention can be widely used in related industrial fields such as pharmaceutical ...

Pharmaceutical composition containing fk506 derivative for treating fungal infection caused by genus cryptococcus and genus candida and use thereof

The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida , and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida , the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention, is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.

MICROFLUIDIC DEVICE FOR CEREBROVASCULAR SIMULATION AND HIGH-EFFICIENCY BLOOD-BRAIN BARRIER SIMULATION SYSTEM COMPRISING SAME

The present disclosure provides a microfluidic device for simulating a blood-brain barrier and a blood-brain barrier simulation system including the same, and the microfluidic device includes: a first channel; a second channel which is adjacently connected to the first channel through one or more microholes and configured to culture neural stem cells; and a chamber which is connected to both ends of the first channel and contains a culture medium. 1. A microfluidic device for simulating a neurovascular unit , comprising:a first channel;a second channel which is adjacently connected to the first channel through one or more microholes and configured to culture neural stem cells; anda chamber which is connected to both ends of the first channel and contains a culture medium.2. The microfluidic device of claim 1 ,wherein an inner surface of the first channel is coated with a coating solution containing at least one selected from the group consisting of poly-L-lysine and collagen.3. The microfluidic device of claim 1 , further comprising:endothelial cells adhered and cultured on an inner surface of the first channel.4. The microfluidic device of claim 3 , further comprising:pericytes adhered and cultured on lower ends of the endothelial cells and the inner surface of the first channel.5. The microfluidic device of claim 1 ,wherein the second channel includes a hydrogel for culturing the neural stem cells in three dimensions.6. The microfluidic device of claim 1 ,wherein the hydrogel includes collagen and crosslinked or non-crosslinked hyaluronic acid.7. The microfluidic device of claim 6 ,wherein the concentration of the collagen in the hydrogel is from 3.0 mg/ml to 5.0 mg/ml, and the concentration of the crosslinked or non-crosslinked hyaluronic acid in the hydrogel is from 1.0 mg/ml to 10.0 mg/ml.9. The microfluidic device of claim 1 ,wherein the culture medium is a medium in which an EGM-2 basal medium and a DMEM/F12 basal medium are mixed.10. The microfluidic device ...

NOVEL GENE REGULATING VIRULENCE OF CRYPTOCOCCUS NEOFORMANS, AND USE THEREOF

The present invention relates to a novel gene regulating the virulence of , and a use thereof. According to the present invention, anti-Cryptococcal or anti-fungal drug candidate materials can be effectively screened for. In addition, the present invention relates to a method for screening for drug candidate materials, which can bring a synergistic effect by being co-administered with a commercially available anti-Cryptococcal drug or anti-fungal drug. Furthermore, provided is a pharmaceutical composition having an anti-Cryptococcal or anti-fungal effect by increasing or decreasing the expression of transcription factors. The present inventors have performed a large-scale virulence test by using insect and animal models so as to identity transcription factors, and have analyzed a complex correlation between the transcription factors and in vivo and in vitro phenotypes of pathogenicity. 1. A method for screening an antifungal agent , comprising the steps of:{'i': 'Cryptococcus neoformans', '(a) bringing a sample to be analyzed into contact with a cell containing an antifungal agent-targeting gene;'}(b) measuring expression of the antifungal agent-targeting gene in the cell; and(c) determining that the sample is an antifungal agent, when the expression of the antifungal agent-targeting gene is down-regulated, wherein the antifungal agent-targeting gene is any one gene selected from the group consisting of an antibacterial agent resistance regulatory gene, a growth regulatory gene, a mating regulatory gene, and a gene that regulates responses to external stress,wherein the antibacterial agent resistance regulatory gene is a gene that regulates resistance to any one antifungal agent selected from the group consisting of azole-, polyene-, 5-flucytocin- and phenylpyrazole-based antifungal agents, wherein the gene that regulates resistance to the azole-based antifungal agent is any one gene selected from the group consisting of alpha, asg1, bap1, bap2, bzp/hxl1, bzp2, bzp3 ...

Functional derivative compounds of alanine and proline amino acids and pharmaceutical composition comprising same

The present invention relates to novel functional derivatives of alanine and proline amino acids. The compounds of the present invention were confirmed to have a very superior antifungal or fungicidal effect. In addition, the compounds of the present invention were confirmed to exhibit a synergistic effect when co-administered with an existing antifungal preparation. Moreover, the compounds of the present invention showed activity on a wide range of fungi. Therefore, the compounds of the present invention can be widely used in a field which requires the treatment with an antifungal or fungicidal preparation against human infectious fungi, animal infectious fungi, and phytopathogenic fungi.

Novel gene regulating virulence ofcryptococcus neoformans

The present invention relates to a novel gene regulating the virulence of Cryptococcus neoformans, and a use thereof. According to the present invention, anti-Cryptococcal or anti-fungal drug candidate materials can be effectively screened for. In addition, the present invention relates to a method for screening for drug candidate materials, which can bring a synergistic effect by being co-administered with a commercially available anti-Cryptococcal drug or anti-fungal drug. Furthermore, provided is a pharmaceutical composition having an anti-Cryptococcal or anti-fungal effect by increasing or decreasing the expression of transcription factors. The present inventors have performed a large-scale virulence test by using insect and animal models so as to identity transcription factors, and have analyzed a complex correlation between the transcription factors and in vivo and in vitro phenotypes of pathogenicity.

Functional derivative compounds of alanine and proline amino acids and pharmaceutical composition comprising same

Novel kinase for treating and preventing fungal infections, and use thereof

The present invention relates to a use of kinases for treating and preventing fungal meningoencephalitis by pathogenic fungi of the genus Cryptococcus. Specifically, the present invention relates to a method for screening an antifungal agent characterized by measuring the amount or activity of a pathogenic-regulatory kinase protein of Cryptococcus neoformans, or the expression level of a gene encoding the protein; and an antifungal pharmaceutical composition comprising an inhibitor against a pathogenic-regulatory kinase protein of Cryptococcus neoformans or a gene encoding the same. An antifungal agent for treating meningoencephalitis, etc. can be effectively screened by using the method for screening an antifungal agent according to the present invention, and meningoencephalitis, etc. can be effectively treated by using the antifungal pharmaceutical composition according to the present invention. Thus, the present invention can be widely used in related industrial fields such as pharmaceutical and biotechnology fields.

Microfluidic device for cerebrovascular simulation and high-efficiency blood-brain barrier simulation system comprising same

The present disclosure provides a microfluidic device for simulating a blood-brain barrier and a blood-brain barrier simulation system including the same, and the microfluidic device includes: a first channel; a second channel which is adjacently connected to the first channel through one or more microholes and configured to culture neural stem cells; and a chamber which is connected to both ends of the first channel and contains a culture medium.

Compostos derivativos funcionais de aminoácidos prolina e alanina e composição farmacêutica compreendendo os mesmos

A presente invenção se refere a novos derivativos funcionais de aminoácidos prolina e alanina. Confirmou-se que os compostos da presente invenção têm um efeito antifúngico e fungicida muito superior. Adicionalmente, confirmou-se que os compostos da presente invenção exibem um efeito sinérgico quando coadministrados com uma preparação antifúngica existente. Ademais, os compostos da presente invenção podem ser amplamente usados em um campo que é requerido o tratamento com uma preparação antifúngica ou fungicida contra infecções por fungo em humanos, infecções por fungo em animais, e fungos fitopatogênicos.

Functional derivative compounds of alanine and proline amino acids and pharmaceutical composition comprising same

The present invention relates to novel functional derivatives of alanine and proline amino acids. The compounds of the present invention were confirmed to have a very superior antifungal or fungicidal effect. In addition, the compounds of the present invention were confirmed to exhibit a synergistic effect when co-administered with an existing antifungal preparation. Moreover, the compounds of the present invention showed activity on a wide range of fungi. Therefore, the compounds of the present invention can be widely used in a field which requires the treatment with an antifungal or fungicidal preparation against human infectious fungi, animal infectious fungi, and phytopathogenic fungi.

Nuevo derivado del acido aminoalcanoico que contiene un grupo bifenilo y una composicion farmaceutica antifungica que comprende el mismo.

La presente invención se refiere a un derivado funcional de aminoácidos de alanina y prolina con el fin de proporcionar derivados, y sales y/o solvatos de los mismos en los que se introduce un grupo bifenilo en un nuevo ácido aminoalcanoico. Se encontró que el compuesto de la presente invención tiene excelentes efectos antifúngicos y fungicidas. Además, se confirmó que el compuesto de la presente invención exhibe un efecto sinérgico cuando se administra en combinación con un agente antifúngico existente. Además, el compuesto de la presente invención ha mostrado actividad contra una amplia gama de hongos. Por lo tanto, el compuesto de la presente invención puede usarse ampliamente en campos que requieren tratamiento con agentes antifúngicos o fungicidas contra hongos patógenos de los seres humanos y hongos patógenos de animales y hongos fitopatógenos.

Un nuevo derivado del ácido aminoalcanoico que contiene un grupo bifenilo y una composición farmacéutica antifúngica que lo comprende

La presente invención se refiere a un compuesto derivado en el que se introduce un grupo bifenilo en un ácido aminoalcanoico, un estereoisómero del mismo o una sal farmacéuticamente aceptable del mismo. El compuesto de la presente invención exhibe excelentes efectos antifúngicos y fungicidas. Además, el compuesto de la presente invención exhibe un efecto sinérgico cuando se usa en combinación con un agente antifúngico convencional. Además, el compuesto de la presente invención proporciona una actividad antifúngica de amplio espectro contra una amplia gama de patógenos fúngicos. Por lo tanto, el compuesto de la presente invención puede usarse ampliamente en campos que requieren tratamiento con agentes antifúngicos o fungicidas contra hongos patógenos humanos y hongos patógenos animales, y hongos fitopatógenos.

A novel aminoalkanoic acid derivative containing a biphenyl group and an antifungal pharmaceutical composition comprising the same

The present invention relates to a functional derivative of alanine and proline amino acids for the purpose of providing derivatives, and salts and/or solvates thereof in which a biphenyl group is introduced into a novel aminoalkanoic acid. The compound of the present invention was found to have very excellent antifungal and fungicidal effects. Also, it was confirmed that the compound of the present invention exhibits a synergistic effect when administered in combination with an existing antifungal agent. Furthermore, the compound of the present invention has shown activity against a wide range of fungi. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

Composto derivado introduzindo o grupo bifenila no novo ácido aminoalcanoico e composição farmacêutica antifúngica compreendendo o mesmo

composto derivado introduzindo o grupo bifenila no novo ácido aminoalcanoico e composição farmacêutica antifúngica compreendendo o mesmo. a presente invenção se refere a um derivado funcional de aminoácidos alanina e prolina para o propósito de fornecer derivados, e sais e/ou solvatos dos mesmos em que um grupo bifenila é introduzido em um novo ácido aminoalcanoico. verificou-se que o composto da presente invenção tem efeitos antifúngicos e fungicidas muito excelentes. além disso, foi confirmado que o composto da presente invenção exibe um efeito sinérgico quando administrado em combinação com um agente antifúngico existente. além disso, o composto da presente invenção mostrou atividade contra uma ampla faixa de fungos. portanto, o composto da presente invenção pode ser amplamente usado em campos que requerem tratamento com agentes antifúngicos ou fungicidas contra fungos patogênicos humanos e fungos patogênicos animais, e fungos fitopatogênicos.

Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same

Method for preparing aminoalkanoic acid derivative containing biphenyl group

The present invention relates to a derivative compound in which a biphenyl group is introduced into an aminoalkanoic acid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent antifungal and fungicidal effects. Furthermore, the compound of the present invention exhibits a synergistic effect when used in combination with a conventional antifungal agent. Furthermore, the compound of the present invention provides broad-spectrum antifungal activity against a wide range of fungal pathogens. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

Aminoalkanoic acid derivative containing biphenyl group and use of the same

The present invention relates to a derivative compound in which a biphenyl group is introduced into an aminoalkanoic acid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent antifungal and fungicidal effects. Furthermore, the compound of the present invention exhibits a synergistic effect when used in combination with a conventional antifungal agent. Furthermore, the compound of the present invention provides broad-spectrum antifungal activity against a wide range of fungal pathogens. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group

The present invention relates to a derivative compound in which a biphenyl group is introduced into an aminoalkanoic acid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent antifungal and fungicidal effects. Furthermore, the compound of the present invention exhibits a synergistic effect when used in combination with a conventional antifungal agent. Furthermore, the compound of the present invention provides broad-spectrum antifungal activity against a wide range of fungal pathogens. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

Nowy gen regulujący wirulencję cryptococcus neoformans i jego zastosowanie

Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same

Nuevo gen que regula la virulencia de Cryptococcus neoformans, y utilización del mismo

La presente invención se refiere a un nuevo gen que regula la virulencia de Cryptococcus neoformans y a su uso. Según la presente invención, se pueden detectar eficazmente materiales candidatos a fármacos anticriptocócicos o antifúngicos. Además, la presente invención se refiere a un método para detectar materiales candidatos a fármacos, que pueden aportar un efecto sinérgico al coadministrarse con un fármaco anticriptocócico o antifúngico disponible comercialmente. Además, se proporciona una composición farmacéutica que tiene un efecto anticriptocócico o antifúngico al aumentar o disminuir la expresión de factores de transcripción. Los presentes inventores han realizado una prueba de virulencia a gran escala utilizando modelos de insectos y animales para identificar factores de transcripción, y han analizado una correlación compleja entre los factores de transcripción y los fenotipos de patogenicidad in vivo e in vitro. (Traducción automática con Google Translate, sin valor legal)

Composición farmacéutica que contiene un derivado de FK506 para el tratamiento de una infección fúngica causada por el género Cryptococcus y el género Candida y su uso

La presente invención se relaciona con una composición farmacéutica que contiene el derivado FK506 para el tratamiento de una infección fúngica causada por el género Cryptococcus o el género Candida, y un uso de la misma. Además, la presente invención se refiere a un agente terapéutico para la infección fúngica causada por el género Cryptococcus o el género Candida, que contiene el derivado FK506 del agente terapéutico. La composición farmacéutica de la presente invención es inocua para el cuerpo humano y puede contribuir en gran medida a proporcionar fármacos antifúngicos con un excelente efecto antifúngico. (Traducción automática con Google Translate, sin valor legal)

Nyt gen der regulerer virulens af cryptococcus neoformans, og anvendelse deraf

Pharmaceutical composition containing fk506 derivative for treating fungal infection caused by genus cryptococcus and genus candida and use thereof

Pharmaceutical composition containing fk506 derivative for treating fungal infection caused by genus cryptococcus and genus candida and use thereof

Pharmaceutical composition containing FK506 derivative for treating fungal infection caused by genus Cryptococcus and genus Candida and use thereof

The present invention relates to a pharmaceutical composition containing FK506 derivative for treating a fungal infection caused by the genus Cryptococcus or the genus Candida , and a use thereof. In addition, the present invention relates to a therapeutic agent for fungal infection caused by the genus Cryptococcus or the genus Candida , the therapeutic agent containing FK506 derivative. The pharmaceutical composition of the present invention is harmless to the human body, and can make a great contribution to providing antifungal drugs with an excellent antifungal effect.

Use of gene involved in passage through brain-blood barrier and survival inside brain of causative fungi of meningoencephalitis

The present invention relates to: a method for screening an antifungal agent, the method measuring the amount or activity of proteins involved in passage through the brain-blood barrier; a biomarker composition for diagnosing meningoencephalitis or cryptococcosis; a diagnostic kit including said composition; and a therapeutic pharmaceutical composition including an inhibitor for the protein.

Use of gene involved in passage through brain-blood barrier and survival inside brain of causative fungi of meningoencephalitis

Novel gene regulating virulence of cryptococcus neoformans, and use thereof

Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same

Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group

The present invention relates to a derivative compound in which a biphenyl group is introduced into an aminoalkanoic acid, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits excellent antifungal and fungicidal effects. Furthermore, the compound of the present invention exhibits a synergistic effect when used in combination with a conventional antifungal agent. Furthermore, the compound of the present invention provides broad-spectrum antifungal activity against a wide range of fungal pathogens. Therefore, the compound of the present invention may be widely used in fields requiring treatment with antifungal or fungicidal agents against human pathogenic fungi and animal pathogenic fungi, and phytopathogenic fungi.

Nowatorska pochodna kwasu aminoalkanowego, zawierająca w swojej strukturze ugrupowanie bifenylowe, oraz kompozycja farmaceutyczna o działaniu przeciwgrzybiczym, w skład której wchodzi ta pochodna

Compuesto derivado que introduce un grupo bifenilo en un nuevo ácido aminoalcanoico y composición farmacéutica antifúngica que comprende el mismo